JP4934433B2 - 超分子コンストラクトを含む方法および組成物 - Google Patents

超分子コンストラクトを含む方法および組成物 Download PDF

Info

Publication number
JP4934433B2
JP4934433B2 JP2006554250A JP2006554250A JP4934433B2 JP 4934433 B2 JP4934433 B2 JP 4934433B2 JP 2006554250 A JP2006554250 A JP 2006554250A JP 2006554250 A JP2006554250 A JP 2006554250A JP 4934433 B2 JP4934433 B2 JP 4934433B2
Authority
JP
Japan
Prior art keywords
peptide
composition
amyloid
antibodies
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006554250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527870A (ja
JP2007527870A5 (enExample
Inventor
イヴ クロード ニコラウ
ルース グルフェラス
デビッド ヒックマン
Original Assignee
エーシー イミューン ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/783,975 external-priority patent/US20040242845A1/en
Priority claimed from US10/958,211 external-priority patent/US8663650B2/en
Application filed by エーシー イミューン ソシエテ アノニム filed Critical エーシー イミューン ソシエテ アノニム
Publication of JP2007527870A publication Critical patent/JP2007527870A/ja
Publication of JP2007527870A5 publication Critical patent/JP2007527870A5/ja
Application granted granted Critical
Publication of JP4934433B2 publication Critical patent/JP4934433B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2006554250A 2004-02-20 2005-02-22 超分子コンストラクトを含む方法および組成物 Expired - Fee Related JP4934433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/783,975 US20040242845A1 (en) 2003-02-21 2004-02-20 Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US10/783,975 2004-02-20
US10/958,211 US8663650B2 (en) 2003-02-21 2004-10-04 Methods and compositions comprising supramolecular constructs
US10/958,211 2004-10-04
PCT/US2005/005285 WO2005081872A2 (en) 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011131772A Division JP2011251964A (ja) 2004-02-20 2011-06-14 超分子コンストラクトを含む方法および組成物

Publications (3)

Publication Number Publication Date
JP2007527870A JP2007527870A (ja) 2007-10-04
JP2007527870A5 JP2007527870A5 (enExample) 2011-08-04
JP4934433B2 true JP4934433B2 (ja) 2012-05-16

Family

ID=46395388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006554250A Expired - Fee Related JP4934433B2 (ja) 2004-02-20 2005-02-22 超分子コンストラクトを含む方法および組成物

Country Status (10)

Country Link
JP (1) JP4934433B2 (enExample)
KR (1) KR101277004B1 (enExample)
CY (1) CY1116316T1 (enExample)
DK (1) DK2465533T3 (enExample)
ES (2) ES2385226T3 (enExample)
HR (1) HRP20150612T1 (enExample)
HU (1) HUE025186T2 (enExample)
PT (1) PT2465533E (enExample)
RS (1) RS54074B1 (enExample)
SI (1) SI2465533T1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
JP6027011B2 (ja) * 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
JP2002500165A (ja) * 1997-12-31 2002-01-08 オラソマル テクノロジーズ,インコーポレーテッド 新規の重合性の脂肪酸、リン脂質、及びそれから得られた重合リポソーム
JP2003518151A (ja) * 1999-12-22 2003-06-03 シアウォーター・コーポレイション ポリ(エチレングリコール)の1−ベンゾトリアゾリル炭酸エステルの調製のための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500165A (ja) * 1997-12-31 2002-01-08 オラソマル テクノロジーズ,インコーポレーテッド 新規の重合性の脂肪酸、リン脂質、及びそれから得られた重合リポソーム
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
JP2003518151A (ja) * 1999-12-22 2003-06-03 シアウォーター・コーポレイション ポリ(エチレングリコール)の1−ベンゾトリアゾリル炭酸エステルの調製のための方法

Also Published As

Publication number Publication date
SI2465533T1 (sl) 2015-07-31
DK2465533T3 (en) 2015-04-20
ES2539262T3 (es) 2015-06-29
ES2385226T9 (es) 2013-10-10
HK1172260A1 (en) 2013-04-19
ES2385226T3 (es) 2012-07-19
HK1130698A1 (en) 2010-01-08
CY1116316T1 (el) 2017-02-08
HRP20150612T1 (hr) 2015-07-03
HUE025186T2 (en) 2016-02-29
JP2007527870A (ja) 2007-10-04
PT2465533E (pt) 2015-06-24
KR101277004B1 (ko) 2013-06-24
RS54074B1 (sr) 2015-10-30
KR20120097546A (ko) 2012-09-04

Similar Documents

Publication Publication Date Title
US9975946B2 (en) Antibodies obtainable using supramolecular constructs
US7772375B2 (en) Monoclonal antibodies that recognize epitopes of amyloid-beta
JP5810076B2 (ja) 薬学的組成物
CN101330923B (zh) 治疗性疫苗
US20040242845A1 (en) Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
JP4934433B2 (ja) 超分子コンストラクトを含む方法および組成物
HK1172260B (en) Methods and compositions comprising supramolecular constructs
HK1130698B (en) Methods and compositions comprising supramolecular constructs

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110317

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120220

R150 Certificate of patent or registration of utility model

Ref document number: 4934433

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees